First, we developed a rodent model of late-stage T2D that involved rigorous model characterization, extensive insulin titration protocols for adequate depth and duration of hypoglycemia and efficacy testing with two SSTR2 antagonist compounds. This evidence concerns the gene INS and type 2 diabetes mellitus.